Daily Stock Analysis, ADMP, Adamis Pharmaceuticals Corp, priceseries

Adamis Pharmaceuticals Corp. Daily Stock Analysis
Stock Information
Open
5.20
Close
5.25
High
5.35
Low
5.10
Previous Close
5.20
Daily Price Gain
0.05
YTD High
6.45
YTD High Date
Jun 16, 2017
YTD Low
2.80
YTD Low Date
Jan 19, 2017
YTD Price Change
2.00
YTD Gain
61.54%
52 Week High
6.45
52 Week High Date
Jun 16, 2017
52 Week Low
2.40
52 Week Low Date
Oct 27, 2016
52 Week Price Change
1.86
52 Week Gain
54.87%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 9. 2015
4.06
Sep 23. 2015
4.30
10 Trading Days
5.80%
Link
LONG
Nov 20. 2015
4.15
Dec 9. 2015
4.95
12 Trading Days
19.32%
Link
LONG
Feb 12. 2016
4.60
Mar 8. 2016
5.69
16 Trading Days
23.64%
Link
LONG
Mar 18. 2016
5.47
Mar 28. 2016
5.76
5 Trading Days
5.30%
Link
LONG
Apr 13. 2016
6.89
May 11. 2016
8.62
20 Trading Days
25.06%
Link
LONG
Feb 7. 2017
3.15
Feb 22. 2017
3.32
10 Trading Days
5.44%
Link
LONG
Mar 6. 2017
3.75
Mar 21. 2017
4.34
11 Trading Days
15.79%
Link
LONG
Jun 15. 2017
5.75
Jun 16. 2017
6.10
1 Trading Days
6.09%
Link
LONG
Aug 21. 2017
4.85
Sep 7. 2017
5.43
13 Trading Days
11.96%
Link
Company Information
Stock Symbol
ADMP
Exchange
NasdaqCM
Company URL
http://http://www.adamispharmaceuticals.com
Company Phone
(858) 997-2400
CEO
Dennis J. Carlo
Headquarters
California
Business Address
11455 EL CAMINO REAL, SUITE 310, SAN DIEGO, CA 92130
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Delivery
CIK
0000887247
About

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of allergy and respiratory disease.

Description

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of allergy and respiratory disease. Its specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease; and APC-2000 for the treatment of bronchospasms. The company also has various biotechnology product candidates and technologies, including therapeutic vaccine and cancer product candidates that comprise TeloB-VAX (vaccine), APC-100, APC-200, and APC-300, which are under development for the treatment of prostate cancer. In addition, it operates a 503B drug outsourcing facility that provides prescription medications to patients, physician clinics, hospitals, and surgery centers in the United States. The company is headquartered in San Diego, California.